ACTIVE_NOT_RECRUITING

Testing the Addition of an Anti-cancer Drug, Pembrolizumab, to the Usual Intravesical Chemotherapy Treatment (Gemcitabine) for the Treatment of BCG-Unresponsive Non-muscle Invasive Bladder Cancer

Conditions

Bladder Flat Urothelial Carcinoma In Situ Non-Muscle Invasive Bladder Urothelial Carcinoma Stage 0a Bladder Cancer AJCC v8 Stage 0is Bladder Cancer AJCC v8 Stage I Bladder Cancer AJCC v8

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

This phase II trial studies the effect of adding pembrolizumab to gemcitabine in treating patients with non-muscle invasive bladder cancer whose cancer does not respond to Bacillus Calmette-Guerin (BCG) treatment. Chemotherapy drugs, such as gemcitabine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the patient's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Adding pembrolizumab to gemcitabine may delay the return of BCG-unresponsive bladder cancer for longer period compared to gemcitabine alone.

Official Title

Phase II Trial of Intravesical Gemcitabine and MK-3475 (Pembrolizumab) in the Treatment of Patients With BCG-Unresponsive Non-Muscle Invasive Bladder Cancer

Quick Facts

Study Start:2020-03-18

Study Completion:2026-03-31

Study Type:Not specified

Phase:Not Applicable

Enrollment:Not specified

Status:ACTIVE_NOT_RECRUITING

Study ID

NCT04164082

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years

Sexes Eligible for Study:ALL

Accepts Healthy Volunteers:No

Standard Ages:ADULT, OLDER_ADULT

Inclusion Criteria	Exclusion Criteria
* High grade Ta, T1 or CIS urothelial carcinoma. Accrual of patients with Ta or T1 disease may be closed to ensure adequate patients enrollment to meet the primary endpoint * Persistent disease (defined as not achieving disease free status) after completing therapy with at least induction BCG (\>= 5 doses) and the first round of maintenance or second induction course (\>= 2 doses). The subsequent round of BCG, either maintenance or repeat induction, must be given within 6 months of initial induction BCG * Persistent high risk NMIBC (T1, high grade Ta and/or CIS) must be within 9 months of the last BCG instillation despite having received adequate BCG as defined above. * Registration must be within 12 months of last BCG instillation * High grade T1 after completing therapy with at least induction BCG (\>= 5 doses) or after completing therapy with at least induction BCG (\>= 5 doses) and first round of maintenance or second induction course (\>= 2 doses). The subsequent round of BCG, either maintenance or repeat induction, must be given within 6 months of initial induction BCG * Disease recurrence (T1) must be within 9 months of the last BCG instillation despite having received adequate BCG as defined above * Registration must be within 12 months of last BCG instillation * Mixed variant histology (adenocarcinoma, squamous cell carcinoma) is eligible, but pure variant histology is ineligible * Patients who are disease free at 6 months after starting BCG but have high grade recurrence (T1, Ta, CIS) while on maintenance therapy would be eligible * The recurrence must be within 6 months of the last BCG dose. * Registration must be within 12 months of last maintenance BCG instillation * Patients must be deemed unfit for radical cystectomy by the treating physician or refuse radical cystectomy * All patients must have histologically confirmed urothelial cancer of the bladder within 60 days prior to registration * All visible tumor must be completely resected 60 days prior to registration (residual pure CIS is permitted) * All patients must have had a cystoscopy (or TURBT with complete resection) without papillary tumor and negative urinary cytology within 28 days of registration (positive cytology is allowed in patients with CIS) * All patients with T1 tumors must undergo a re-staging transurethral resection of bladder tumor (TURBT) within 60 days of registration * There must be uninvolved muscularis propria present in the re-staging TURBT. The initial TURBT prior to re-staging TURBT may be greater than 60 days prior to registration * Patients must have had imaging with CT or MRI abdomen/pelvis within 90 days of registration demonstrating no evidence of metastasis * Patients cannot have had a history of urothelial carcinoma in the ureters or prostatic urethra 24 months prior to registration * Patients must not be currently participating in or have participated in a study of an investigational agent or have used an investigational device within 4 weeks prior to study registration * Note: Participants who have entered the follow-up phase of an investigational study may participate as long as it has been more than 4 weeks after the last dose of the previous investigational agent at time of registration * Patients must not have prior therapy with an anti-PD-1, anti-PD-L1, or anti PD L2 agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor (e.g., CTLA-4, OX 40, CD137) * Patients must not have undergone prior allogeneic hematopoietic stem cell transplantation within the last 5 years prior to registration. (Participants who have had a transplant greater than 5 years ago are eligible as long as there are no symptoms of graft versus host disease \[GVHD\]) * Patients must not have received prior systemic anti-cancer therapy including investigational agents within 4 weeks prior to treatment * Note: Participants must have recovered from all adverse events (AEs) due to previous therapies to =\< grade 1 or baseline. Participants with =\< grade 2 neuropathy may be eligible * Note: If participant received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting study treatment * Patients must not have received prior radiotherapy within 2 weeks of study registration. Participants must have recovered from all radiation-related toxicities, not require corticosteroids, and not have had radiation pneumonitis * Patients must not have received radiation therapy to the lung that is \> 30 Gy within 6 months prior to trial registration * Not pregnant and not nursing, because this study involves an agent that has known genotoxic, mutagenic and teratogenic effects * Women and men of reproductive potential should agree to use an appropriate method of birth control throughout their participation in this study due to the teratogenic potential of the therapy utilized in this trial. Include as applicable: Appropriate methods of birth control include abstinence, oral contraceptives, implantable hormonal contraceptives or double barrier method (diaphragm plus condom) * A woman of childbearing potential (WOCBP) must not have a positive urine pregnancy test within 7 days prior to registration. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required * Patients must not be pregnant or breastfeeding or expecting to conceive or father children within the projected duration of the study, starting with registration through the last dose of treatment * Age \>= 18 years * Eastern Cooperative Oncology Group (ECOG) performance status 0-2 * Absolute neutrophil count (ANC) \>= 1,500/mm\^3 * Platelet count \>= 100,000/mm\^3 * Hemoglobin \>= 9.0 g/dL * Creatinine =\< 1.5 x upper limit of normal (ULN) * In patients with creatinine \> 1.5 x ULN, if measured or calculated creatinine clearance \> 30 mL/min, then patient is eligible * Total bilirubin =\< 1.5 x ULN * In patients with a total bilirubin \> 1.5 x ULN, if direct bilirubin \< 1.0 X ULN, then patient is eligible * Aspartate aminotransferase (AST)/ alanine aminotransferase (ALT) =\< 2.5 x ULN * Patients must not have had an active autoimmune disease requiring systemic treatment within 24 months prior to registration. Autoimmune diseases include, but not limited to, lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, antiphospholipid syndrome, Wegener's granulomatosis, Sjogren's syndrome, Bell's palsy, Guillain-Barre syndrome, multiple sclerosis, autoimmune thyroid disease, vasculitis, or glomerulonephritis * Patients must not have a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior to registration * Note: Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency) is not considered a form of systemic treatment and is allowed * Patients must not have a known psychiatric or substance abuse disorder that would interfere with the participant's ability to cooperate with the requirements of the study * Patients must not have active tuberculosis * Patients must not have been treated with antibiotics for an active infection within 14 days prior to registration. Prophylactic antibiotics are permitted. Treatment for a urinary tract infection (UTI) is allowed but must be deemed adequately treated by the treating physician prior the start of cycle 1 (C1) day 1 (D1) * Patients must not have a history of idiopathic pulmonary fibrosis or organizing pneumonia * Patients must not have a history of (non-infectious) pneumonitis that required steroids or have current pneumonitis * Patients with human immunodeficiency virus (HIV) are eligible with the following: * On effective anti-retroviral therapy with undetectable viral load within 6 months of registration * HIV-infected participants must not have a history of Kaposi sarcoma and/or multicentric Castleman disease * Patients must not have a known additional malignancy that has had progression or has required active treatment in the last three years. Exceptions include basal or squamous cell carcinoma of the skin that has undergone potentially curative therapy or in situ cervical cancer. A history of prostate cancer that was treated with definitive intent is allowed, provided that the prostate-specific antigen (PSA) is undetectable for at least 1 year while off androgen deprivation therapy * Patients must not have known active CNS metastases and/or carcinomatous meningitis. Participants with previously treated brain metastases may participate provided they are radiologically stable, i.e., without evidence of progression for at least 4 weeks by repeat imaging (note that the repeat imaging should be performed during study screening), clinically stable and without requirement of steroid treatment for at least 14 days prior to first dose of study treatment * Patients must not have severe hypersensitivity (\>= grade 3) to pembrolizumab and/or any of its excipients * Patients must not have an active infection requiring systemic therapy * Patients must not have a known history of hepatitis B (defined as hepatitis B surface antigen \[HBsAg\] reactive) or known active hepatitis C virus (defined as hepatitis C virus \[HCV\] ribonucleic acid \[RNA\] \[qualitative\] is detected) infection * Note: No testing for hepatitis B and hepatitis C is required unless mandated by a local health authority * Patients must not have received live vaccines within 30 days of study drug administration. Examples of live vaccines include, but are not limited to, the following: measles, mumps, rubella, varicella/zoster (chicken pox), yellow fever, rabies, Bacillus Calmette-Guerin (BCG), and typhoid vaccine. Seasonal influenza vaccines for injection are generally killed virus vaccines and are allowed; however, intranasal influenza vaccines (e.g., FluMist®) are live attenuated vaccines and are not allowed. COVID-19 vaccinations are permitted	Pregnancy or breastfeeding Severe psychiatric disorders Active substance abuse Unstable medical conditions Inability to comply with study requirements

Inclusion Criteria

Exclusion Criteria

* High grade Ta, T1 or CIS urothelial carcinoma. Accrual of patients with Ta or T1 disease may be closed to ensure adequate patients enrollment to meet the primary endpoint
* Persistent disease (defined as not achieving disease free status) after completing therapy with at least induction BCG (\>= 5 doses) and the first round of maintenance or second induction course (\>= 2 doses). The subsequent round of BCG, either maintenance or repeat induction, must be given within 6 months of initial induction BCG
* Persistent high risk NMIBC (T1, high grade Ta and/or CIS) must be within 9 months of the last BCG instillation despite having received adequate BCG as defined above.
* Registration must be within 12 months of last BCG instillation
* High grade T1 after completing therapy with at least induction BCG (\>= 5 doses) or after completing therapy with at least induction BCG (\>= 5 doses) and first round of maintenance or second induction course (\>= 2 doses). The subsequent round of BCG, either maintenance or repeat induction, must be given within 6 months of initial induction BCG
* Disease recurrence (T1) must be within 9 months of the last BCG instillation despite having received adequate BCG as defined above
* Registration must be within 12 months of last BCG instillation
* Mixed variant histology (adenocarcinoma, squamous cell carcinoma) is eligible, but pure variant histology is ineligible
* Patients who are disease free at 6 months after starting BCG but have high grade recurrence (T1, Ta, CIS) while on maintenance therapy would be eligible
* The recurrence must be within 6 months of the last BCG dose.
* Registration must be within 12 months of last maintenance BCG instillation
* Patients must be deemed unfit for radical cystectomy by the treating physician or refuse radical cystectomy
* All patients must have histologically confirmed urothelial cancer of the bladder within 60 days prior to registration
* All visible tumor must be completely resected 60 days prior to registration (residual pure CIS is permitted)
* All patients must have had a cystoscopy (or TURBT with complete resection) without papillary tumor and negative urinary cytology within 28 days of registration (positive cytology is allowed in patients with CIS)
* All patients with T1 tumors must undergo a re-staging transurethral resection of bladder tumor (TURBT) within 60 days of registration
* There must be uninvolved muscularis propria present in the re-staging TURBT. The initial TURBT prior to re-staging TURBT may be greater than 60 days prior to registration
* Patients must have had imaging with CT or MRI abdomen/pelvis within 90 days of registration demonstrating no evidence of metastasis
* Patients cannot have had a history of urothelial carcinoma in the ureters or prostatic urethra 24 months prior to registration
* Patients must not be currently participating in or have participated in a study of an investigational agent or have used an investigational device within 4 weeks prior to study registration
* Note: Participants who have entered the follow-up phase of an investigational study may participate as long as it has been more than 4 weeks after the last dose of the previous investigational agent at time of registration
* Patients must not have prior therapy with an anti-PD-1, anti-PD-L1, or anti PD L2 agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor (e.g., CTLA-4, OX 40, CD137)
* Patients must not have undergone prior allogeneic hematopoietic stem cell transplantation within the last 5 years prior to registration. (Participants who have had a transplant greater than 5 years ago are eligible as long as there are no symptoms of graft versus host disease \[GVHD\])
* Patients must not have received prior systemic anti-cancer therapy including investigational agents within 4 weeks prior to treatment
* Note: Participants must have recovered from all adverse events (AEs) due to previous therapies to =\< grade 1 or baseline. Participants with =\< grade 2 neuropathy may be eligible
* Note: If participant received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting study treatment
* Patients must not have received prior radiotherapy within 2 weeks of study registration. Participants must have recovered from all radiation-related toxicities, not require corticosteroids, and not have had radiation pneumonitis
* Patients must not have received radiation therapy to the lung that is \> 30 Gy within 6 months prior to trial registration
* Not pregnant and not nursing, because this study involves an agent that has known genotoxic, mutagenic and teratogenic effects
* Women and men of reproductive potential should agree to use an appropriate method of birth control throughout their participation in this study due to the teratogenic potential of the therapy utilized in this trial. Include as applicable: Appropriate methods of birth control include abstinence, oral contraceptives, implantable hormonal contraceptives or double barrier method (diaphragm plus condom)
* A woman of childbearing potential (WOCBP) must not have a positive urine pregnancy test within 7 days prior to registration. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required
* Patients must not be pregnant or breastfeeding or expecting to conceive or father children within the projected duration of the study, starting with registration through the last dose of treatment
* Age \>= 18 years
* Eastern Cooperative Oncology Group (ECOG) performance status 0-2
* Absolute neutrophil count (ANC) \>= 1,500/mm\^3
* Platelet count \>= 100,000/mm\^3
* Hemoglobin \>= 9.0 g/dL
* Creatinine =\< 1.5 x upper limit of normal (ULN)
* In patients with creatinine \> 1.5 x ULN, if measured or calculated creatinine clearance \> 30 mL/min, then patient is eligible
* Total bilirubin =\< 1.5 x ULN
* In patients with a total bilirubin \> 1.5 x ULN, if direct bilirubin \< 1.0 X ULN, then patient is eligible
* Aspartate aminotransferase (AST)/ alanine aminotransferase (ALT) =\< 2.5 x ULN
* Patients must not have had an active autoimmune disease requiring systemic treatment within 24 months prior to registration. Autoimmune diseases include, but not limited to, lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, antiphospholipid syndrome, Wegener's granulomatosis, Sjogren's syndrome, Bell's palsy, Guillain-Barre syndrome, multiple sclerosis, autoimmune thyroid disease, vasculitis, or glomerulonephritis
* Patients must not have a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior to registration
* Note: Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency) is not considered a form of systemic treatment and is allowed
* Patients must not have a known psychiatric or substance abuse disorder that would interfere with the participant's ability to cooperate with the requirements of the study
* Patients must not have active tuberculosis
* Patients must not have been treated with antibiotics for an active infection within 14 days prior to registration. Prophylactic antibiotics are permitted. Treatment for a urinary tract infection (UTI) is allowed but must be deemed adequately treated by the treating physician prior the start of cycle 1 (C1) day 1 (D1)
* Patients must not have a history of idiopathic pulmonary fibrosis or organizing pneumonia
* Patients must not have a history of (non-infectious) pneumonitis that required steroids or have current pneumonitis
* Patients with human immunodeficiency virus (HIV) are eligible with the following:
* On effective anti-retroviral therapy with undetectable viral load within 6 months of registration
* HIV-infected participants must not have a history of Kaposi sarcoma and/or multicentric Castleman disease
* Patients must not have a known additional malignancy that has had progression or has required active treatment in the last three years. Exceptions include basal or squamous cell carcinoma of the skin that has undergone potentially curative therapy or in situ cervical cancer. A history of prostate cancer that was treated with definitive intent is allowed, provided that the prostate-specific antigen (PSA) is undetectable for at least 1 year while off androgen deprivation therapy
* Patients must not have known active CNS metastases and/or carcinomatous meningitis. Participants with previously treated brain metastases may participate provided they are radiologically stable, i.e., without evidence of progression for at least 4 weeks by repeat imaging (note that the repeat imaging should be performed during study screening), clinically stable and without requirement of steroid treatment for at least 14 days prior to first dose of study treatment
* Patients must not have severe hypersensitivity (\>= grade 3) to pembrolizumab and/or any of its excipients
* Patients must not have an active infection requiring systemic therapy
* Patients must not have a known history of hepatitis B (defined as hepatitis B surface antigen \[HBsAg\] reactive) or known active hepatitis C virus (defined as hepatitis C virus \[HCV\] ribonucleic acid \[RNA\] \[qualitative\] is detected) infection
* Note: No testing for hepatitis B and hepatitis C is required unless mandated by a local health authority
* Patients must not have received live vaccines within 30 days of study drug administration. Examples of live vaccines include, but are not limited to, the following: measles, mumps, rubella, varicella/zoster (chicken pox), yellow fever, rabies, Bacillus Calmette-Guerin (BCG), and typhoid vaccine. Seasonal influenza vaccines for injection are generally killed virus vaccines and are allowed; however, intranasal influenza vaccines (e.g., FluMist®) are live attenuated vaccines and are not allowed. COVID-19 vaccinations are permitted

Pregnancy or breastfeeding
Severe psychiatric disorders
Active substance abuse
Unstable medical conditions
Inability to comply with study requirements

Contacts and Locations

Principal Investigator

Michael E Woods

PRINCIPAL_INVESTIGATOR

Alliance for Clinical Trials in Oncology

Study Locations (Sites)

University of Alabama at Birmingham Cancer Center

Birmingham, Alabama, 35233

United States

Anchorage Associates in Radiation Medicine

Anchorage, Alaska, 98508

United States

Anchorage Radiation Therapy Center

Anchorage, Alaska, 99504

United States

Alaska Breast Care and Surgery LLC

Anchorage, Alaska, 99508

United States

Alaska Oncology and Hematology LLC

Anchorage, Alaska, 99508

United States

Alaska Women's Cancer Care

Anchorage, Alaska, 99508

United States

Anchorage Oncology Centre

Anchorage, Alaska, 99508

United States

Katmai Oncology Group

Anchorage, Alaska, 99508

United States

Providence Alaska Medical Center

Anchorage, Alaska, 99508

United States

Fairbanks Memorial Hospital

Fairbanks, Alaska, 99701

United States

Cancer Center at Saint Joseph's

Phoenix, Arizona, 85004

United States

Mayo Clinic Hospital in Arizona

Phoenix, Arizona, 85054

United States

Mayo Clinic in Arizona

Scottsdale, Arizona, 85259

United States

Mercy Hospital Fort Smith

Fort Smith, Arkansas, 72903

United States

Providence Saint Joseph Medical Center/Disney Family Cancer Center

Burbank, California, 91505

United States

Cedars Sinai Medical Center

Los Angeles, California, 90048

United States

University of California Davis Comprehensive Cancer Center

Sacramento, California, 95817

United States

Rocky Mountain Cancer Centers-Aurora

Aurora, Colorado, 80012

United States

The Medical Center of Aurora

Aurora, Colorado, 80012

United States

Boulder Community Hospital

Boulder, Colorado, 80301

United States

Boulder Community Foothills Hospital

Boulder, Colorado, 80303

United States

Rocky Mountain Cancer Centers-Boulder

Boulder, Colorado, 80304

United States

Rocky Mountain Cancer Centers - Centennial

Centennial, Colorado, 80112

United States

Cancer Center of Colorado at Sloan's Lake

Denver, Colorado, 80204

United States

National Jewish Health-Main Campus

Denver, Colorado, 80206

United States

The Women's Imaging Center

Denver, Colorado, 80209

United States

Colorado Blood Cancer Institute

Denver, Colorado, 80218

United States

Presbyterian - Saint Lukes Medical Center - Health One

Denver, Colorado, 80218

United States

Rocky Mountain Cancer Centers-Midtown

Denver, Colorado, 80218

United States

Saint Joseph Hospital - Cancer Centers of Colorado

Denver, Colorado, 80218

United States

Rocky Mountain Cancer Centers-Rose

Denver, Colorado, 80220

United States

Rose Medical Center

Denver, Colorado, 80220

United States

Western Surgical Care

Denver, Colorado, 80220

United States

Mountain Blue Cancer Care Center - Swedish

Englewood, Colorado, 80113

United States

Rocky Mountain Cancer Centers - Swedish

Englewood, Colorado, 80113

United States

Swedish Medical Center

Englewood, Colorado, 80113

United States

The Melanoma and Skin Cancer Institute

Englewood, Colorado, 80113

United States

National Jewish Health-Western Hematology Oncology

Golden, Colorado, 80401

United States

Saint Mary's Hospital and Regional Medical Center

Grand Junction, Colorado, 81501

United States

Banner North Colorado Medical Center

Greeley, Colorado, 80631

United States

Good Samaritan Hospital - Cancer Centers of Colorado

Lafayette, Colorado, 80026

United States

Rocky Mountain Cancer Centers-Lakewood

Lakewood, Colorado, 80228

United States

Rocky Mountain Cancer Centers-Littleton

Littleton, Colorado, 80120

United States

Rocky Mountain Cancer Centers-Sky Ridge

Lone Tree, Colorado, 80124

United States

Sky Ridge Medical Center

Lone Tree, Colorado, 80124

United States

Banner McKee Medical Center

Loveland, Colorado, 80539

United States

National Jewish Health-Northern Hematology Oncology

Thornton, Colorado, 80260

United States

Rocky Mountain Cancer Centers-Thornton

Thornton, Colorado, 80260

United States

Intermountain Health Lutheran Hospital

Wheat Ridge, Colorado, 80401

United States

MedStar Georgetown University Hospital

Washington, District of Columbia, 20007

United States

MedStar Washington Hospital Center

Washington, District of Columbia, 20010

United States

Holy Cross Hospital

Fort Lauderdale, Florida, 33308

United States

University of Florida Health Science Center - Gainesville

Gainesville, Florida, 32610

United States

Hawaii Cancer Care - Westridge

'Aiea, Hawaii, 96701

United States

Pali Momi Medical Center

'Aiea, Hawaii, 96701

United States

Queen's Cancer Center - Pearlridge

'Aiea, Hawaii, 96701

United States

The Cancer Center of Hawaii-Pali Momi

'Aiea, Hawaii, 96701

United States

The Queen's Medical Center - West Oahu

'Ewa Beach, Hawaii, 96706

United States

Hawaii Cancer Care Inc - Waterfront Plaza

Honolulu, Hawaii, 96813

United States

Island Urology

Honolulu, Hawaii, 96813

United States

Queen's Cancer Cenrer - POB I

Honolulu, Hawaii, 96813

United States

Queen's Medical Center

Honolulu, Hawaii, 96813

United States

Straub Clinic and Hospital

Honolulu, Hawaii, 96813

United States

University of Hawaii Cancer Center

Honolulu, Hawaii, 96813

United States

Hawaii Cancer Care Inc-Liliha

Honolulu, Hawaii, 96817

United States

Hawaii Diagnostic Radiology Services LLC

Honolulu, Hawaii, 96817

United States

Kuakini Medical Center

Honolulu, Hawaii, 96817

United States

Queen's Cancer Center - Kuakini

Honolulu, Hawaii, 96817

United States

The Cancer Center of Hawaii-Liliha

Honolulu, Hawaii, 96817

United States

Kapiolani Medical Center for Women and Children

Honolulu, Hawaii, 96826

United States

Straub Medical Center - Kahului Clinic

Kahului, Hawaii, 96732

United States

Castle Medical Center

Kailua, Hawaii, 96734

United States

Wilcox Memorial Hospital and Kauai Medical Clinic

Lihue, Hawaii, 96766

United States

Saint Alphonsus Cancer Care Center-Boise

Boise, Idaho, 83706

United States

Saint Luke's Cancer Institute - Boise

Boise, Idaho, 83712

United States

Saint Alphonsus Cancer Care Center-Caldwell

Caldwell, Idaho, 83605

United States

Kootenai Health - Coeur d'Alene

Coeur d'Alene, Idaho, 83814

United States

Walter Knox Memorial Hospital

Emmett, Idaho, 83617

United States

Saint Luke's Cancer Institute - Fruitland

Fruitland, Idaho, 83619

United States

Idaho Urologic Institute-Meridian

Meridian, Idaho, 83642

United States

Saint Luke's Cancer Institute - Meridian

Meridian, Idaho, 83642

United States

Saint Alphonsus Cancer Care Center-Nampa

Nampa, Idaho, 83687

United States

Saint Luke's Cancer Institute - Nampa

Nampa, Idaho, 83687

United States

Kootenai Clinic Cancer Services - Post Falls

Post Falls, Idaho, 83854

United States

Kootenai Clinic Cancer Services - Sandpoint

Sandpoint, Idaho, 83864

United States

Saint Luke's Cancer Institute - Twin Falls

Twin Falls, Idaho, 83301

United States

OSF Saint Anthony's Health Center

Alton, Illinois, 62002

United States

Illinois CancerCare-Bloomington

Bloomington, Illinois, 61704

United States

Illinois CancerCare-Canton

Canton, Illinois, 61520

United States

Memorial Hospital of Carbondale

Carbondale, Illinois, 62902

United States

SIH Cancer Institute

Carterville, Illinois, 62918

United States

Illinois CancerCare-Carthage

Carthage, Illinois, 62321

United States

Centralia Oncology Clinic

Centralia, Illinois, 62801

United States

Rush University Medical Center

Chicago, Illinois, 60612

United States

Cancer Care Specialists of Illinois - Decatur

Decatur, Illinois, 62526

United States

Decatur Memorial Hospital

Decatur, Illinois, 62526

United States

Illinois CancerCare-Dixon

Dixon, Illinois, 61021

United States

Crossroads Cancer Center

Effingham, Illinois, 62401

United States

Illinois CancerCare-Eureka

Eureka, Illinois, 61530

United States

Illinois CancerCare-Galesburg

Galesburg, Illinois, 61401

United States

Western Illinois Cancer Treatment Center

Galesburg, Illinois, 61401

United States

Illinois CancerCare-Kewanee Clinic

Kewanee, Illinois, 61443

United States

Illinois CancerCare-Macomb

Macomb, Illinois, 61455

United States

Loyola University Medical Center

Maywood, Illinois, 60153

United States

Marjorie Weinberg Cancer Center at Loyola-Gottlieb

Melrose Park, Illinois, 60160

United States

SSM Health Good Samaritan

Mount Vernon, Illinois, 62864

United States

Cancer Care Center of O'Fallon

O'Fallon, Illinois, 62269

United States

Illinois CancerCare-Ottawa Clinic

Ottawa, Illinois, 61350

United States

Illinois CancerCare-Pekin

Pekin, Illinois, 61554

United States

Illinois CancerCare-Peoria

Peoria, Illinois, 61615

United States

Methodist Medical Center of Illinois

Peoria, Illinois, 61636

United States

Illinois CancerCare-Peru

Peru, Illinois, 61354

United States

Valley Radiation Oncology

Peru, Illinois, 61354

United States

Illinois CancerCare-Princeton

Princeton, Illinois, 61356

United States

Southern Illinois University School of Medicine

Springfield, Illinois, 62702

United States

Springfield Clinic

Springfield, Illinois, 62702

United States

Springfield Memorial Hospital

Springfield, Illinois, 62781

United States

Southwest Illinois Health Services LLP

Swansea, Illinois, 62226

United States

Illinois CancerCare - Washington

Washington, Illinois, 61571

United States

Reid Health

Richmond, Indiana, 47374

United States

Memorial Hospital of South Bend

South Bend, Indiana, 46601

United States

Central Care Cancer Center - Garden City

Garden City, Kansas, 67846

United States

Central Care Cancer Center - Great Bend

Great Bend, Kansas, 67530

United States

University of Kansas Cancer Center

Kansas City, Kansas, 66160

United States

University of Kansas Hospital-Indian Creek Campus

Overland Park, Kansas, 66211

United States

University of Kansas Hospital-Westwood Cancer Center

Westwood, Kansas, 66205

United States

University of Kentucky/Markey Cancer Center

Lexington, Kentucky, 40536

United States

Louisiana Hematology Oncology Associates LLC

Baton Rouge, Louisiana, 70809

United States

Mary Bird Perkins Cancer Center

Baton Rouge, Louisiana, 70809

United States

Mary Bird Perkins Cancer Center - Metairie

Metairie, Louisiana, 70002

United States

East Jefferson General Hospital

Metairie, Louisiana, 70006

United States

LSU Healthcare Network / Metairie Multi-Specialty Clinic

Metairie, Louisiana, 70006

United States

Louisiana State University Health Science Center

New Orleans, Louisiana, 70112

United States

University Medical Center New Orleans

New Orleans, Louisiana, 70112

United States

Touro Infirmary

New Orleans, Louisiana, 70115

United States

UM Baltimore Washington Medical Center/Tate Cancer Center

Glen Burnie, Maryland, 21061

United States

Lowell General Hospital

Lowell, Massachusetts, 01854

United States

Mercy Medical Center

Springfield, Massachusetts, 01104

United States

Hickman Cancer Center

Adrian, Michigan, 49221

United States

Trinity Health Saint Joseph Mercy Hospital Ann Arbor

Ann Arbor, Michigan, 48106

United States

Bronson Battle Creek

Battle Creek, Michigan, 49017

United States

Trinity Health IHA Medical Group Hematology Oncology - Brighton

Brighton, Michigan, 48114

United States

Trinity Health Medical Center - Brighton

Brighton, Michigan, 48114

United States

Trinity Health IHA Medical Group Hematology Oncology - Canton

Canton, Michigan, 48188

United States

Trinity Health Medical Center - Canton

Canton, Michigan, 48188

United States

Caro Cancer Center

Caro, Michigan, 48723

United States

Chelsea Hospital

Chelsea, Michigan, 48118

United States

Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital

Chelsea, Michigan, 48118

United States

Hematology Oncology Consultants-Clarkston

Clarkston, Michigan, 48346

United States

Newland Medical Associates-Clarkston

Clarkston, Michigan, 48346

United States

Henry Ford Health Saint John Hospital

Detroit, Michigan, 48236

United States

Henry Ford River District Hospital

East China Township, Michigan, 48054

United States

Cancer Hematology Centers - Flint

Flint, Michigan, 48503

United States

Genesee Hematology Oncology PC

Flint, Michigan, 48503

United States

Genesys Hurley Cancer Institute

Flint, Michigan, 48503

United States

Hurley Medical Center

Flint, Michigan, 48503

United States

Corewell Health Grand Rapids Hospitals - Butterworth Hospital

Grand Rapids, Michigan, 49503

United States

Corewell Health Grand Rapids Hospitals - Helen DeVos Children's Hospital

Grand Rapids, Michigan, 49503

United States

Trinity Health Grand Rapids Hospital

Grand Rapids, Michigan, 49503

United States

Henry Ford Saint John Hospital - Academic

Grosse Pointe Woods, Michigan, 48236

United States

Henry Ford Saint John Hospital - Breast

Grosse Pointe Woods, Michigan, 48236

United States

Henry Ford Saint John Hospital - Van Elslander

Grosse Pointe Woods, Michigan, 48236

United States

Bronson Methodist Hospital

Kalamazoo, Michigan, 49007

United States

West Michigan Cancer Center

Kalamazoo, Michigan, 49007

United States

Ascension Borgess Cancer Center

Kalamazoo, Michigan, 49009

United States

Ascension Borgess Hospital

Kalamazoo, Michigan, 49048

United States

University of Michigan Health - Sparrow Lansing

Lansing, Michigan, 48912

United States

Hope Cancer Clinic

Livonia, Michigan, 48154

United States

Trinity Health Saint Mary Mercy Livonia Hospital

Livonia, Michigan, 48154

United States

Henry Ford Saint John Hospital - Macomb Medical

Macomb, Michigan, 48044

United States

Henry Ford Warren Hospital - Breast Macomb

Macomb, Michigan, 48044

United States

Saint Mary's Oncology/Hematology Associates of Marlette

Marlette, Michigan, 48453

United States

Toledo Clinic Cancer Centers-Monroe

Monroe, Michigan, 48162

United States

Trinity Health Muskegon Hospital

Muskegon, Michigan, 49444

United States

Corewell Health Lakeland Hospitals - Niles Hospital

Niles, Michigan, 49120

United States

Cancer and Hematology Centers of Western Michigan - Norton Shores

Norton Shores, Michigan, 49444

United States

Hope Cancer Center

Pontiac, Michigan, 48341

United States

Michigan Healthcare Professionals Pontiac

Pontiac, Michigan, 48341

United States

Newland Medical Associates-Pontiac

Pontiac, Michigan, 48341

United States

Trinity Health Saint Joseph Mercy Oakland Hospital

Pontiac, Michigan, 48341

United States

Corewell Health Reed City Hospital

Reed City, Michigan, 49677

United States

Henry Ford Rochester Hospital

Rochester Hills, Michigan, 48309

United States

MyMichigan Medical Center Saginaw

Saginaw, Michigan, 48601

United States

Oncology Hematology Associates of Saginaw Valley PC

Saginaw, Michigan, 48604

United States

Corewell Health Lakeland Hospitals - Marie Yeager Cancer Center

Saint Joseph, Michigan, 49085

United States

Corewell Health Lakeland Hospitals - Saint Joseph Hospital

Saint Joseph, Michigan, 49085

United States

Bhadresh Nayak MD PC-Sterling Heights

Sterling Heights, Michigan, 48312

United States

MyMichigan Medical Center Tawas

Tawas City, Michigan, 48764

United States

Munson Medical Center

Traverse City, Michigan, 49684

United States

Advanced Breast Care Center PLLC

Warren, Michigan, 48088

United States

Henry Ford Health Warren Hospital

Warren, Michigan, 48093

United States

Henry Ford Madison Heights Hospital - Breast

Warren, Michigan, 48093

United States

Henry Ford Warren Hospital - GLCMS

Warren, Michigan, 48093

United States

Macomb Hematology Oncology PC

Warren, Michigan, 48093

United States

Saint Mary's Oncology/Hematology Associates of West Branch

West Branch, Michigan, 48661

United States

University of Michigan Health - West

Wyoming, Michigan, 49519

United States

Huron Gastroenterology PC

Ypsilanti, Michigan, 48106

United States

Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus

Ypsilanti, Michigan, 48197

United States

Fairview Ridges Hospital

Burnsville, Minnesota, 55337

United States

Minnesota Oncology - Burnsville

Burnsville, Minnesota, 55337

United States

Cambridge Medical Center

Cambridge, Minnesota, 55008

United States

Mercy Hospital

Coon Rapids, Minnesota, 55433

United States

Fairview Southdale Hospital

Edina, Minnesota, 55435

United States

Unity Hospital

Fridley, Minnesota, 55432

United States

Fairview Clinics and Surgery Center Maple Grove

Maple Grove, Minnesota, 55369

United States

Minnesota Oncology Hematology PA-Maplewood

Maplewood, Minnesota, 55109

United States

Saint John's Hospital - Healtheast

Maplewood, Minnesota, 55109

United States

Abbott-Northwestern Hospital

Minneapolis, Minnesota, 55407

United States

Hennepin County Medical Center

Minneapolis, Minnesota, 55415

United States

Health Partners Inc

Minneapolis, Minnesota, 55454

United States

Monticello Cancer Center

Monticello, Minnesota, 55362

United States

New Ulm Medical Center

New Ulm, Minnesota, 56073

United States

Fairview Northland Medical Center

Princeton, Minnesota, 55371

United States

North Memorial Medical Health Center

Robbinsdale, Minnesota, 55422

United States

Park Nicollet Clinic - Saint Louis Park

Saint Louis Park, Minnesota, 55416

United States

Regions Hospital

Saint Paul, Minnesota, 55101

United States

United Hospital

Saint Paul, Minnesota, 55102

United States

Saint Francis Regional Medical Center

Shakopee, Minnesota, 55379

United States

Lakeview Hospital

Stillwater, Minnesota, 55082

United States

Ridgeview Medical Center

Waconia, Minnesota, 55387

United States

Rice Memorial Hospital

Willmar, Minnesota, 56201

United States

Minnesota Oncology Hematology PA-Woodbury

Woodbury, Minnesota, 55125

United States

Fairview Lakes Medical Center

Wyoming, Minnesota, 55092

United States

Mercy Oncology and Hematology - Clayton-Clarkson

Ballwin, Missouri, 63011

United States

Central Care Cancer Center - Bolivar

Bolivar, Missouri, 65613

United States

Cox Cancer Center Branson

Branson, Missouri, 65616

United States

Mercy Cancer Center - Cape Girardeau

Cape Girardeau, Missouri, 63703

United States

Saint Francis Medical Center

Cape Girardeau, Missouri, 63703

United States

Saint Luke's Hospital

Chesterfield, Missouri, 63017

United States

MU Health - University Hospital/Ellis Fischel Cancer Center

Columbia, Missouri, 65212

United States

Parkland Health Center - Farmington

Farmington, Missouri, 63640

United States

MU Health Care Goldschmidt Cancer Center

Jefferson City, Missouri, 65109

United States

Freeman Health System

Joplin, Missouri, 64804

United States

Mercy Hospital Joplin

Joplin, Missouri, 64804

United States

Mercy Clinic-Rolla-Cancer and Hematology

Rolla, Missouri, 65401

United States

Phelps Health Delbert Day Cancer Institute

Rolla, Missouri, 65401

United States

Heartland Regional Medical Center

Saint Joseph, Missouri, 64506

United States

Saint Louis Cancer and Breast Institute-South City

Saint Louis, Missouri, 63109

United States

Mercy Hospital South

Saint Louis, Missouri, 63128

United States

Missouri Baptist Medical Center

Saint Louis, Missouri, 63131

United States

Mercy Hospital Saint Louis

Saint Louis, Missouri, 63141

United States

Sainte Genevieve County Memorial Hospital

Sainte Genevieve, Missouri, 63670

United States

Mercy Hospital Springfield

Springfield, Missouri, 65804

United States

CoxHealth South Hospital

Springfield, Missouri, 65807

United States

Missouri Baptist Sullivan Hospital

Sullivan, Missouri, 63080

United States

BJC Outpatient Center at Sunset Hills

Sunset Hills, Missouri, 63127

United States

Mercy Hospital Washington

Washington, Missouri, 63090

United States

Community Hospital of Anaconda

Anaconda, Montana, 59711

United States

Billings Clinic Cancer Center

Billings, Montana, 59101

United States

Saint Vincent Healthcare

Billings, Montana, 59101

United States

Saint Vincent Frontier Cancer Center

Billings, Montana, 59102

United States

Bozeman Health Deaconess Hospital

Bozeman, Montana, 59715

United States

Saint James Community Hospital and Cancer Treatment Center

Butte, Montana, 59701

United States

Benefis Sletten Cancer Institute

Great Falls, Montana, 59405

United States

Great Falls Clinic

Great Falls, Montana, 59405

United States

Logan Health Medical Center

Kalispell, Montana, 59901

United States

Saint Patrick Hospital - Community Hospital

Missoula, Montana, 59802

United States

Community Medical Center

Missoula, Montana, 59804

United States

Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center

Lebanon, New Hampshire, 03756

United States

Memorial Sloan Kettering Basking Ridge

Basking Ridge, New Jersey, 07920

United States

Hackensack University Medical Center

Hackensack, New Jersey, 07601

United States

Memorial Sloan Kettering Monmouth

Middletown, New Jersey, 07748

United States

Memorial Sloan Kettering Bergen

Montvale, New Jersey, 07645

United States

The Valley Hospital - Luckow Pavilion

Paramus, New Jersey, 07652

United States

Neurosurgeons of New Jersey-Ridgewood

Ridgewood, New Jersey, 07450

United States

Valley Health System Ridgewood Campus

Ridgewood, New Jersey, 07450

United States

Valley Health System-Hematology/Oncology

Westwood, New Jersey, 07675

United States

Memorial Sloan Kettering Commack

Commack, New York, 11725

United States

Arnot Ogden Medical Center/Falck Cancer Center

Elmira, New York, 14905

United States

The New York Hospital Medical Center of Queens

Flushing, New York, 11355

United States

Memorial Sloan Kettering Westchester

Harrison, New York, 10604

United States

Memorial Sloan Kettering Cancer Center

New York, New York, 10065

United States

NYP/Weill Cornell Medical Center

New York, New York, 10065

United States

Stony Brook University Medical Center

Stony Brook, New York, 11794

United States

Memorial Sloan Kettering Nassau

Uniondale, New York, 11553

United States

UNC Lineberger Comprehensive Cancer Center

Chapel Hill, North Carolina, 27599

United States

University of North Carolina-Hillsborough Campus

Hillsborough, North Carolina, 27278

United States

Indu and Raj Soin Medical Center

Beavercreek, Ohio, 45431

United States

Saint Elizabeth Boardman Hospital

Boardman, Ohio, 44512

United States

Dayton Physicians LLC-Miami Valley South

Centerville, Ohio, 45459

United States

Miami Valley Hospital South

Centerville, Ohio, 45459

United States

Oncology Hematology Care Inc-Kenwood

Cincinnati, Ohio, 45236

United States

Miami Valley Hospital

Dayton, Ohio, 45409

United States

Dayton Physician LLC - Englewood

Dayton, Ohio, 45415

United States

Miami Valley Hospital North

Dayton, Ohio, 45415

United States

Armes Family Cancer Center

Findlay, Ohio, 45840

United States

Blanchard Valley Hospital

Findlay, Ohio, 45840

United States

Orion Cancer Care

Findlay, Ohio, 45840

United States

Atrium Medical Center-Middletown Regional Hospital

Franklin, Ohio, 45005-1066

United States

Dayton Physicians LLC-Atrium

Franklin, Ohio, 45005

United States

Dayton Physicians LLC-Wayne

Greenville, Ohio, 45331

United States

Wayne Hospital

Greenville, Ohio, 45331

United States

Greater Dayton Cancer Center

Kettering, Ohio, 45409

United States

First Dayton Cancer Care

Kettering, Ohio, 45420

United States

Kettering Medical Center

Kettering, Ohio, 45429

United States

Mercy Health - Perrysburg Hospital

Perrysburg, Ohio, 43551

United States

Springfield Regional Cancer Center

Springfield, Ohio, 45504

United States

Springfield Regional Medical Center

Springfield, Ohio, 45504

United States

Mercy Health - Saint Anne Hospital

Toledo, Ohio, 43623

United States

Toledo Clinic Cancer Centers-Toledo

Toledo, Ohio, 43623

United States

Dayton Physicians LLC - Troy

Troy, Ohio, 45373

United States

Upper Valley Medical Center

Troy, Ohio, 45373

United States

Saint Joseph Warren Hospital

Warren, Ohio, 44484

United States

Saint Elizabeth Youngstown Hospital

Youngstown, Ohio, 44501

United States

University of Oklahoma Health Sciences Center

Oklahoma City, Oklahoma, 73104

United States

Mercy Hospital Oklahoma City

Oklahoma City, Oklahoma, 73120

United States

Saint Alphonsus Cancer Care Center-Baker City

Baker City, Oregon, 97814

United States

Saint Charles Health System

Bend, Oregon, 97701

United States

Clackamas Radiation Oncology Center

Clackamas, Oregon, 97015

United States

Providence Cancer Institute Clackamas Clinic

Clackamas, Oregon, 97015

United States

Bay Area Hospital

Coos Bay, Oregon, 97420

United States

Providence Newberg Medical Center

Newberg, Oregon, 97132

United States

Saint Alphonsus Cancer Care Center-Ontario

Ontario, Oregon, 97914

United States

Providence Portland Medical Center

Portland, Oregon, 97213

United States

Providence Saint Vincent Medical Center

Portland, Oregon, 97225

United States

Saint Charles Health System-Redmond

Redmond, Oregon, 97756

United States

Lehigh Valley Hospital-Cedar Crest

Allentown, Pennsylvania, 18103

United States

Lehigh Valley Hospital - Muhlenberg

Bethlehem, Pennsylvania, 18017

United States

Pocono Medical Center

East Stroudsburg, Pennsylvania, 18301

United States

Lehigh Valley Hospital-Hazleton

Hazleton, Pennsylvania, 18201

United States

Ralph H Johnson VA Medical Center

Charleston, South Carolina, 29401

United States

Gibbs Cancer Center-Gaffney

Gaffney, South Carolina, 29341

United States

Gibbs Cancer Center-Pelham

Greer, South Carolina, 29651

United States

North Grove Medical Park

Spartanburg, South Carolina, 29303

United States

Spartanburg Medical Center

Spartanburg, South Carolina, 29303

United States

Spartanburg Medical Center - Mary Black Campus

Spartanburg, South Carolina, 29307

United States

SMC Center for Hematology Oncology Union

Union, South Carolina, 29379

United States

University of Texas Medical Branch

Galveston, Texas, 77555-0565

United States

Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center

Houston, Texas, 77030

United States

UTMB Cancer Center at Victory Lakes

League City, Texas, 77573

United States

Audie L Murphy VA Hospital

San Antonio, Texas, 78229

United States

University of Texas Health Science Center at San Antonio

San Antonio, Texas, 78229

United States

American Fork Hospital / Huntsman Intermountain Cancer Center

American Fork, Utah, 84003

United States

Sandra L Maxwell Cancer Center

Cedar City, Utah, 84720

United States

Logan Regional Hospital

Logan, Utah, 84321

United States

Intermountain Medical Center

Murray, Utah, 84107

United States

McKay-Dee Hospital Center

Ogden, Utah, 84403

United States

Utah Valley Regional Medical Center

Provo, Utah, 84604

United States

Riverton Hospital

Riverton, Utah, 84065

United States

Saint George Regional Medical Center

Saint George, Utah, 84770

United States

Utah Cancer Specialists-Salt Lake City

Salt Lake City, Utah, 84106

United States

LDS Hospital

Salt Lake City, Utah, 84143

United States

Providence Regional Cancer System-Aberdeen

Aberdeen, Washington, 98520

United States

MultiCare Auburn Medical Center

Auburn, Washington, 98001

United States

PeaceHealth Saint Joseph Medical Center

Bellingham, Washington, 98225

United States

Providence Regional Cancer System-Centralia

Centralia, Washington, 98531

United States

Swedish Cancer Institute-Edmonds

Edmonds, Washington, 98026

United States

Providence Regional Cancer Partnership

Everett, Washington, 98201

United States

MultiCare Gig Harbor Medical Park

Gig Harbor, Washington, 98335

United States

Swedish Cancer Institute-Issaquah

Issaquah, Washington, 98029

United States

Kadlec Clinic Hematology and Oncology

Kennewick, Washington, 99336

United States

Providence Regional Cancer System-Lacey

Lacey, Washington, 98503

United States

PeaceHealth Saint John Medical Center

Longview, Washington, 98632

United States

Jefferson Healthcare

Port Townsend, Washington, 98368

United States

MultiCare Good Samaritan Hospital

Puyallup, Washington, 98372

United States

Pacific Gynecology Specialists

Seattle, Washington, 98104

United States

Swedish Medical Center-Ballard Campus

Seattle, Washington, 98107

United States

Swedish Medical Center-Cherry Hill

Seattle, Washington, 98122-5711

United States

Swedish Medical Center-First Hill

Seattle, Washington, 98122

United States

PeaceHealth United General Medical Center

Sedro-Woolley, Washington, 98284

United States

Providence Regional Cancer System-Shelton

Shelton, Washington, 98584

United States

MultiCare Deaconess Cancer and Blood Specialty Center - Valley

Spokane Valley, Washington, 99216

United States

MultiCare Deaconess Cancer and Blood Specialty Center - Downtown

Spokane, Washington, 99204

United States

MultiCare Deaconess Cancer and Blood Specialty Center - North

Spokane, Washington, 99218

United States

MultiCare Tacoma General Hospital

Tacoma, Washington, 98405

United States

PeaceHealth Southwest Medical Center

Vancouver, Washington, 98664

United States

Providence Saint Mary Regional Cancer Center

Walla Walla, Washington, 99362

United States

Providence Regional Cancer System-Yelm

Yelm, Washington, 98597

United States

Marshfield Medical Center-EC Cancer Center

Eau Claire, Wisconsin, 54701

United States

Marshfield Medical Center-Marshfield

Marshfield, Wisconsin, 54449

United States

Medical College of Wisconsin

Milwaukee, Wisconsin, 53226

United States

Marshfield Medical Center - Minocqua

Minocqua, Wisconsin, 54548

United States

ProHealth D N Greenwald Center

Mukwonago, Wisconsin, 53149

United States

Cancer Center of Western Wisconsin

New Richmond, Wisconsin, 54017

United States

ProHealth Oconomowoc Memorial Hospital

Oconomowoc, Wisconsin, 53066

United States

Marshfield Medical Center-Rice Lake

Rice Lake, Wisconsin, 54868

United States

Marshfield Medical Center-River Region at Stevens Point

Stevens Point, Wisconsin, 54482

United States

ProHealth Waukesha Memorial Hospital

Waukesha, Wisconsin, 53188

United States

UW Cancer Center at ProHealth Care

Waukesha, Wisconsin, 53188

United States

Marshfield Medical Center - Weston

Weston, Wisconsin, 54476

United States

Cheyenne Regional Medical Center-West

Cheyenne, Wyoming, 82001

United States

Billings Clinic-Cody

Cody, Wyoming, 82414

United States

Welch Cancer Center

Sheridan, Wyoming, 82801

United States

Collaborators and Investigators

Sponsor: National Cancer Institute (NCI)

Michael E Woods, PRINCIPAL_INVESTIGATOR, Alliance for Clinical Trials in Oncology

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2020-03-18

Study Completion Date2026-03-31

Study Record Updates

Study Start Date2020-03-18

Study Completion Date2026-03-31

Terms related to this study

Additional Relevant MeSH Terms

Bladder Flat Urothelial Carcinoma In Situ
Non-Muscle Invasive Bladder Urothelial Carcinoma
Stage 0a Bladder Cancer AJCC v8
Stage 0is Bladder Cancer AJCC v8
Stage I Bladder Cancer AJCC v8